Bristol (BMY) Holding Has Boosted by Hikari Power Ltd; Biotelemetry (BEAT) Holder Parametric Portfolio Associates Has Lowered Its Stake as Share Value Rose

February 25, 2018 - By Michael Collier

Parametric Portfolio Associates Llc decreased its stake in Biotelemetry Inc (BEAT) by 55.57% based on its latest 2017Q3 regulatory filing with the SEC. Parametric Portfolio Associates Llc sold 58,473 shares as the company’s stock rose 13.43% with the market. The institutional investor held 46,760 shares of the health care company at the end of 2017Q3, valued at $1.54M, down from 105,233 at the end of the previous reported quarter. Parametric Portfolio Associates Llc who had been investing in Biotelemetry Inc for a number of months, seems to be less bullish one the $1.13 billion market cap company. The stock increased 4.99% or $1.65 during the last trading session, reaching $34.7. About 848,161 shares traded or 70.83% up from the average. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 87.79% since February 25, 2017 and is uptrending. It has outperformed by 71.09% the S&P500.

Hikari Power Ltd increased its stake in Bristol (BMY) by 23.44% based on its latest 2017Q3 regulatory filing with the SEC. Hikari Power Ltd bought 16,100 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 84,800 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $5.41M, up from 68,700 at the end of the previous reported quarter. Hikari Power Ltd who had been investing in Bristol for a number of months, seems to be bullish on the $110.93B market cap company. The stock increased 3.05% or $2.01 during the last trading session, reaching $67.95. About 5.24 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since February 25, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.08, from 0.95 in 2017Q2. It improved, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported. Estabrook Management reported 0.23% stake. Security Tru holds 1.48% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 70,651 shares. D E Shaw And reported 0.23% stake. Whalerock Point Partners Ltd Liability Corporation accumulated 0.76% or 33,599 shares. Jane Street Gp Ltd Company has invested 0.03% in Bristol-Myers Squibb Company (NYSE:BMY). 48,887 are held by Mengis Cap Mgmt. Great West Life Assurance Can reported 1.48 million shares or 0.23% of all its holdings. Blackhill owns 466,195 shares or 5.58% of their US portfolio. Artemis Mngmt Llp reported 166,500 shares. Tennessee-based Green Square Capital Ltd Liability Company has invested 0.07% in Bristol-Myers Squibb Company (NYSE:BMY). Maryland-based Proshare Lc has invested 0.15% in Bristol-Myers Squibb Company (NYSE:BMY). Osterweis Management owns 14,523 shares. Grisanti Management Limited Liability stated it has 0.44% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Mitsubishi Ufj Tru And Banking Corp reported 0.4% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY). Farmers Bankshares holds 0.54% in Bristol-Myers Squibb Company (NYSE:BMY) or 13,924 shares.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 9 Hold. Therefore 37% are positive. Bristol-Myers Squibb Company had 73 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Overweight” rating by Morgan Stanley given on Thursday, February 15. The rating was downgraded by Jefferies on Monday, October 16 to “Hold”. Cowen & Co maintained it with “Hold” rating and $6500 target in Monday, July 10 report. The firm earned “Sell” rating on Sunday, July 23 by BMO Capital Markets. The company was maintained on Friday, April 29 by UBS. As per Monday, January 25, the company rating was downgraded by BMO Capital Markets. Barclays Capital maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Tuesday, December 1. Barclays Capital has “Equal Weight” rating and $70 target. The firm has “Underperform” rating given on Tuesday, February 6 by BMO Capital Markets. On Thursday, July 27 the stock rating was maintained by Piper Jaffray with “Hold”. The rating was maintained by Cowen & Co on Monday, September 18 with “Hold”.

Since September 6, 2017, it had 1 buy, and 2 selling transactions for $646,385 activity. 4,000 Bristol-Myers Squibb Company (NYSE:BMY) shares with value of $249,187 were bought by Samuels Theodore R. II. The insider Lynch Thomas J. Jr. sold $335,172.

Among 6 analysts covering BioTelemetry (NASDAQ:BEAT), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 9 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was initiated by Dougherty & Company with “Buy” on Friday, December 2. The firm earned “Buy” rating on Tuesday, April 11 by Dougherty & Company. The company was maintained on Thursday, November 30 by Raymond James. Dougherty & Company maintained BioTelemetry, Inc. (NASDAQ:BEAT) rating on Tuesday, July 28. Dougherty & Company has “Buy” rating and $20 target. The stock of BioTelemetry, Inc. (NASDAQ:BEAT) earned “Buy” rating by Sidoti on Tuesday, September 13.

Parametric Portfolio Associates Llc, which manages about $92.09 billion US Long portfolio, upped its stake in Experian Group Ltd (EXPGY) by 48,310 shares to 811,007 shares, valued at $16.37 million in 2017Q3, according to the filing. It also increased its holding in Fortune Brands Home & Security (NYSE:FBHS) by 21,101 shares in the quarter, for a total of 241,940 shares, and has risen its stake in Shiseido Sponsored Adr (SSDOY).

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.02, from 1.3 in 2017Q2. It turned negative, as 15 investors sold BEAT shares while 66 reduced holdings. 41 funds opened positions while 63 raised stakes. 25.49 million shares or 7.15% more from 23.79 million shares in 2017Q2 were reported. Columbia Prtnrs L L C Investment Management has 54,598 shares for 0.24% of their portfolio. Scout Invests has 0.11% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 122,625 shares. Moreover, Hanseatic Mngmt has 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 28 shares. Fifth Third Bancorp reported 15,341 shares. Tower Research Capital Llc (Trc) accumulated 4,820 shares or 0.01% of the stock. Winslow Evans And Crocker has invested 0.04% in BioTelemetry, Inc. (NASDAQ:BEAT). State Board Of Administration Of Florida Retirement Sys invested in 0% or 12,388 shares. Thompson Siegel And Walmsley Lc has invested 0.21% in BioTelemetry, Inc. (NASDAQ:BEAT). Invesco accumulated 0% or 80,458 shares. Mckinley Capital Delaware reported 157,795 shares or 0.21% of all its holdings. Quantbot Technology Ltd Partnership owns 9,087 shares or 0.03% of their US portfolio. Fiera accumulated 186,221 shares. Concorde Asset Management Lc accumulated 35,813 shares. Farmers & Merchants Invs Inc holds 0% or 257 shares. Westover Advisors Limited Liability Co accumulated 7,079 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: